

**RPG LIFE SCIENCES LIMITED**

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030

(Rs. in Lakhs)

**Statement of Financial Results for the quarter and year ended 31st March 2015**

Particulars	Quarter ended			Year ended	
	31-Mar-19	31-Dec-18	31-Mar-18	31-Mar-19	31-Mar-18
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1 Revenue from Operations	6,880	9,097	8,346	33,016	34,714
2 Other Income	42	2	32	80	98
3 <b>Total Income</b>	<b>6,922</b>	<b>9,099</b>	<b>8,378</b>	<b>33,096</b>	<b>34,812</b>
4 <b>Expenses</b>					
(a) Cost of Materials Consumed	953	1,459	2,237	5,117	7,195
(b) Purchases of Stock-in-Trade	1,212	1,132	1,364	4,516	4,935
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	159	336	(852)	1,371	(669)
(d) Excise Duty	-	-	-	-	319
(e) Employee Benefits Expense	1,991	2,394	2,487	8,993	9,014
(f) Finance Costs	91	99	83	399	380
(g) Depreciation and Amortisation Expense	394	386	368	1,532	1,434
(h) Other Expenses	1,910	2,568	2,252	9,663	10,168
<b>Total Expenses</b>	<b>6,710</b>	<b>8,374</b>	<b>7,939</b>	<b>31,591</b>	<b>32,776</b>
5 <b>Profit before tax</b>	<b>212</b>	<b>725</b>	<b>439</b>	<b>1,505</b>	<b>2,036</b>
6 Income tax expenses					
a. Current Tax	18	120	88	284	385
b. Deferred Tax	40	77	226	140	306
7 <b>Profit for the period</b>	<b>154</b>	<b>528</b>	<b>125</b>	<b>1,081</b>	<b>1,345</b>
8 Other Comprehensive Income					
(i) Items that will not be reclassified to Profit or Loss	(23)	(6)	47	(41)	(22)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	8	2	8	14	8
<b>Other Comprehensive Income Net of Tax</b>	<b>(15)</b>	<b>(4)</b>	<b>55</b>	<b>(27)</b>	<b>(14)</b>
9 <b>Total Comprehensive Income for the period</b>	<b>139</b>	<b>524</b>	<b>180</b>	<b>1,054</b>	<b>1,331</b>
10 Paid-up Equity Share Capital (Face Value of the share - Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323
11 Other Equity				14,727	14,152
12 Total Earning per Share from operations (of Rs. 8/- each) (not annualised):					
(a) Basic	0.93	3.19	0.76	6.54	8.13
(b) Diluted	0.93	3.19	0.76	6.54	8.13

## Statement of Assets and Liabilities as at March 31, 2019

(Rs. in Lakhs)

Particulars	As at 31st March 2019	As at 31st March 2018
	(Audited)	
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	8,251	7,994
Capital work-in-progress	1,012	480
Other intangible assets	4,513	5,086
Intangible assets under development	705	393
Financial assets		
ii . Loans	10	9
iii. Other financial assets	30	28
Deferred tax assets (Net)	618	744
Current Tax asset	125	57
Other non-current assets	151	74
<b>Total non-current assets</b>	<b>15,415</b>	<b>14,865</b>
<b>Current assets</b>		
Inventories	4,104	5,369
Financial assets		
i. Trade receivables	3,890	6,813
ii. Cash and cash equivalents	37	11
iii. Bank balances other than (ii) above	40	83
iv. Other financial assets	96	110
Other current assets	1,542	1,876
<b>Total current assets</b>	<b>9,709</b>	<b>14,262</b>
<b>Total assets</b>	<b>25,124</b>	<b>29,127</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	1,323	1,323
<b>Other equity</b>		
Reserves and Surplus	14,727	14,152
<b>Total equity</b>	<b>16,050</b>	<b>15,475</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
i. Borrowings	658	1,023
i. Other financial liabilities	299	279
Provisions	335	279
<b>Total non-current liabilities</b>	<b>1,292</b>	<b>1,581</b>
<b>Current liabilities</b>		
Financial liabilities		
i. Borrowings	2,904	3,792
ii. Trade payables		
-Total Outstanding Dues of Micro Enterprises and Small Enterprises	-	-
-Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises	2,513	5,187
iii. Other financial liabilities	823	1,503
Provisions	1,033	1,225
Current tax liabilities (Net)	-	20
Other current liabilities	509	344
<b>Total current liabilities</b>	<b>7,782</b>	<b>12,071</b>
<b>Total liabilities</b>	<b>9,074</b>	<b>13,652</b>
<b>Total equity and liabilities</b>	<b>25,124</b>	<b>29,127</b>

**Notes:**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on April 29, 2019.
- 2 Figures for the quarter ended March 31, 2019 and the corresponding quarter ended in the previous year as reported in the financial result are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also the figures upto the end of the third quarter had only been reviewed and not subjected to audit.
- 3 The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- 4 The Government of India introduced the Goods and Service Tax ('GST') from July 1, 2017, consequently the revenue from operations for the quarters ended March 31, 2019, December 31, 2018 and March 31, 2018 are reported net of GST. However revenue for all other periods presented is inclusive of excise duty, where applicable. The Net Revenue from operations (Net of GST/Excise Duty) as applicable are stated below:

Particulars	Quarter ended			Year ended	
	31-Mar-19	31-Dec-18	31-Mar-18	31-Mar-19	31-Mar-18
Revenue from Operations	6,880	9,097	8,346	33,016	34,714
Less: Excise Duty	-	-	-	-	319
Net Revenue from operations	6,880	9,097	8,346	33,016	34,395

- 5 The Board of Directors has recommended a normal dividend of Rs. 2.40 per share of Rs 8/- each (30%) for the year ended March 31, 2019, subject to the approval of members at the ensuing Annual General Meeting.
- 6 The MCA vide notification dated October 11, 2018 has amended Schedule III to the Companies Act, 2013 in respect of certain disclosure. The Company has incorporated appropriate changes in the above results.

For RPG Life Sciences Limited

Yugul Sikri  
Managing Director  
Mumbai, April 29, 2019